Anti-amyloid antibodies for dementia cost tens of thousands of dollars per year and Medicare covers them only for early-stage patients enrolled through an approved registry. Verify the exact drug, its list price, and your coverage eligibility before planning care. Anti-amyloid antibodies are infused drugs that remove amyloid protein from the brain in people with Alzheimer's disease. They do not cure dementia, so cost, eligibility, and safety monitoring shape the decision as much as the prescription.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which drugs are currently in play?
- What do Leqembi and Kisunla cost?
- What does Medicare require you to verify?
- What benefit and safety limits should you expect?
Which drugs are currently in play?
Leqembi (lecanemab) received traditional FDA approval on July 6, 2023, after a confirmatory trial verified clinical benefit in adults with Alzheimer's disease, according to the U.S. Food and Drug Administration. Kisunla (donanemab) was approved on July 2, 2024, for adults with early symptomatic Alzheimer's disease, according to the U.S.
Food and Drug Administration. Aduhelm (aducanumab) is no longer an option. Biogen announced on January 31, 2024, that it would discontinue development and commercialization to reprioritize resources toward Leqembi and other approaches, according to Biogen Inc.
What do Leqembi and Kisunla cost?
Managed Healthcare Executive reported that Eisai set Leqembi's wholesale cost at $26,500 per year, based on biweekly infusions for an average 75-kg patient, in its coverage of the approval. That figure is the drug price alone and does not define what a family will pay after coverage.
Pharmaceutical Technology reported that Eli Lilly priced Kisunla at $695.65 per vial, or about $12,522 for six months and about $32,000 for 12 months, in its report on the approval. Treatment length can affect the total, so ask for a written estimate for six and 12 months.
What does Medicare require you to verify?
The Centers for Medicare & Medicaid Services covers approved amyloid-directed antibodies only under Coverage with Evidence Development, described in its Medicare coverage details. Confirm each point with the prescribing clinic before scheduling infusions.
- Diagnosis of mild cognitive impairment or mild dementia tied to Alzheimer's disease
- Test result confirming amyloid pathology in the brain
- Care from a physician team participating in a CMS-approved registry
What benefit and safety limits should you expect?
Neither drug stops or reverses Alzheimer's disease. Over 18 months, Leqembi slowed decline by 27% and Kisunla by about 35% versus placebo, so patients still declined but more slowly, according to Dementia Capable Cares.
Both drugs carry an FDA boxed warning for ARIA, or brain swelling and small bleeds seen on MRI, with required MRI monitoring. Trials found ARIA in about 21% of Leqembi patients and about 37% of Kisunla patients, mostly without symptoms, according to Dementia Capable Cares. Ask how often MRIs occur, who reviews them, and what symptoms should trigger an urgent call.
